Red Tree Venture Capital

Kivu Biosciences, based in San Francisco, is a biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company aims to deliver superior therapeutics and rapidly advance transformative assets, operating discreetly while focusing on its innovative pipeline.

Engrail Therapeutics, Inc. is dedicated to developing and commercializing neuro drugs aimed at treating diseases of the nervous system. Founded in 2019 and based in San Diego, California, the company focuses on creating transformative medicines to alleviate the significant burden of such conditions. One of its key products is ENX-101, a preclinical compound designed to modulate a receptor for GABA, a critical neurotransmitter in the brain. Engrail Therapeutics combines biological insights with clinically meaningful solutions to advance its portfolio of therapies, utilizing a flexible transaction model to efficiently progress its drug candidates from development to commercialization.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing innovative CAR T-cell therapies to improve outcomes for cancer patients. The company aims to address the challenges faced by existing autologous CAR therapies, which are only curative for less than half of cancer patients and hindered by issues such as manufacturing limitations, supply challenges, and reimbursement barriers. Cargo Therapeutics is advancing next-generation cell therapies designed to enhance effectiveness, safety, and supply reliability. One of its key products, CRG-022, is a novel CAR T-cell candidate targeting CD22, an antigen present in a majority of B-cell malignancies, specifically designed to overcome treatment resistance. By pursuing these novel solutions, Cargo Therapeutics seeks to facilitate broader access to curative therapies and significantly improve the treatment experience for cancer patients.

Tachyon Therapeutics is a biotechnology company focused on research and development aimed at creating innovative therapeutics for cancer treatment. The company is dedicated to developing first-in-class compounds that target new drug mechanisms in cancer biology, employing advanced techniques in molecular cancer biology, epigenetics, and cancer stem cell research. Currently, Tachyon is conducting Phase 1 clinical trials to evaluate the safety, pharmacokinetics, and anti-tumor effectiveness of its lead candidate, TACH101, in patients with advanced cancer. Through a commitment to high-quality and scientifically sound practices, Tachyon aims to provide novel treatment options that unlock new pathways for addressing complex cancer cases.

Alladapt Immunotherapeutics, founded in 2018 and based in Menlo Park, California, is a privately held biopharmaceutical company dedicated to developing therapeutics for food allergy treatment. Its lead product, ADP101, is an oral immunotherapy designed to mitigate allergic reactions triggered by multiple common allergens, offering a broad-spectrum solution for patients with various food allergies.

Rondo Therapeutics is a biopharmaceutical company based in Hayward, California, specializing in the discovery and development of innovative bispecific antibodies aimed at activating the immune system to combat cancer. Founded in 2021, the company focuses on creating cancer immunotherapies specifically for solid tumor types that do not respond to existing immune checkpoint inhibitors. By addressing areas of unmet medical need, Rondo Therapeutics aims to advance novel therapeutic options for patients facing challenging cancer diagnoses.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing innovative CAR T-cell therapies to improve outcomes for cancer patients. The company aims to address the challenges faced by existing autologous CAR therapies, which are only curative for less than half of cancer patients and hindered by issues such as manufacturing limitations, supply challenges, and reimbursement barriers. Cargo Therapeutics is advancing next-generation cell therapies designed to enhance effectiveness, safety, and supply reliability. One of its key products, CRG-022, is a novel CAR T-cell candidate targeting CD22, an antigen present in a majority of B-cell malignancies, specifically designed to overcome treatment resistance. By pursuing these novel solutions, Cargo Therapeutics seeks to facilitate broader access to curative therapies and significantly improve the treatment experience for cancer patients.

Magnus Medical focuses on developing a closed-loop neuromodulation technology aimed at effectively treating intractable neurological and psychiatric disorders. The company's innovative brain stimulation technology has shown the ability to produce profound and rapid results by facilitating identifiable changes in brain networks. This approach enables individuals to manage their symptoms acutely while also working towards restoring and sustaining their mental health over the long term.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

Ceribell, Inc. is a medical technology company based in Mountain View, California, that specializes in the design and manufacture of devices for acquiring and interpreting electroencephalography (EEG) data. Founded in 2014, Ceribell focuses on making EEG technology more accessible, efficient, and cost-effective, particularly in acute care settings. The company's flagship product, the Ceribell EEG System, includes a portable EEG headband and a compact recorder that provide clinical-quality EEG results without the need for a trained EEG technologist. This system can be set up by healthcare providers in just six minutes, facilitating quicker clinical decision-making. An innovative feature of the Ceribell System is its Brain Stethoscope function, which translates brainwave patterns into sound to aid in the detection of seizures, including non-convulsive seizures. This capability enables earlier diagnosis and targeted treatment, potentially reducing mortality, length of hospital stays, and the risk of complications for patients with serious neurological conditions.

Pipeline Therapeutics Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of small molecules aimed at neuroregeneration. Founded in 2017, the company focuses on promoting functional recovery for various neurological disorders. Its lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics has a portfolio of earlier-stage programs, including PIPE-307, which targets remyelination and axonal repair to address conditions like multiple sclerosis. By harnessing the natural repair processes of different nervous system cell types, the company seeks to provide innovative treatments that repair damage within the nervous system.